9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Estimated reading time: < 1 min

Condition: Advanced Solid Tumors

Estimated Enrollment: 490

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Phase I part: Incidence of dose limiting toxicities (DLTs),  Phase II part: Overall response Rate per RECIST V1.1,  AUC, Presence and/ or concentration of anti-LAG525 and anti-PDR001 antibodies

Interventions: LAG525, PDR001

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: May 19, 2020

Completion Date: May 19, 2020

Last  Posted Date: June 21, 2019

Location: Novartis Investigative Site, New York, New York, United States

Website Link: https://ClinicalTrials.gov/show/NCT02460224

Was this article helpful?
Dislike 0